| Market Cap | 25.54M | P/E | - | EPS this Y | 45.10% | Ern Qtrly Grth | - |
| Income | -43.04M | Forward P/E | -1.46 | EPS next Y | 51.00% | 50D Avg Chg | 24.00% |
| Sales | - | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -3.00% |
| Dividend | N/A | Price/Book | 0.41 | EPS next 5Y | 29.90% | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 5.34 | Shares Outstanding | 3.20M | 52W Low Chg | 148.00% |
| Insider Own | 1.66% | ROA | -39.69% | Shares Float | 1.92M | Beta | 0.74 |
| Inst Own | 63.35% | ROE | -75.56% | Shares Shorted/Prior | 36.17K/3.35K | Price | 0.85 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 88,429 | Target Price | 33.00 |
| Oper. Margin | - | Earnings Date | Apr 26 | Volume | 46,358 | Change | 2.91% |
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
